(Q30497303)

English

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer

scientific article published on September 25, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

Bradley J. Monk

8

object named as

Bradley J Monk

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

author name string

Dana Chase

6

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Basmina Parmakhtiar

7

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Patrick Connelly

10

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Koen Degeest

11

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Ernest S. Han

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20870280

20 July 2024

Robert A. Burger

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20870280

20 July 2024

Kathleen M. Darcy

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20870280

20 July 2024

Michael W. Sill

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20870280

20 July 2024

Leslie M. Randall

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20870280

20 July 2024

Benjamin E. Greer

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20870280

20 July 2024

John P. Fruehauf

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20870280

20 July 2024

language of work or name

0 references

publication date

25 September 2010

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

full work available at URL

https://europepmc.org/articles/pmc2975758?pdf=render

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20870280

20 July 2024

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20870280/pdf/?tool=EBI

Portable Document Format

online access status

content deliverer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20870280

20 July 2024

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20870280/?tool=EBI

online access status

content deliverer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20870280

20 July 2024

https://europepmc.org/articles/PMC2975758

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20870280

20 July 2024

https://europepmc.org/articles/PMC2975758?pdf=render

Portable Document Format

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20870280

20 July 2024

https://doi.org/10.1016/j.ygyno.2010.08.016

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20870280

20 July 2024

https://api.elsevier.com/content/article/PII:S0090825810006104?httpAccept=text/xml

1 reference

10.1016/J.YGYNO.2010.08.016

https://api.crossref.org/works/10.1016/J.YGYNO.2010.08.016

20 July 2024

https://api.elsevier.com/content/article/PII:S0090825810006104?httpAccept=text/plain

1 reference

10.1016/J.YGYNO.2010.08.016

https://api.crossref.org/works/10.1016/J.YGYNO.2010.08.016

20 July 2024

Gynecologic Oncology

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

119

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

3

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

484-490

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

Thrombospondins in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

Vascular endothelial growth factor signaling pathways: therapeutic perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

Predicting benefit from anti-angiogenic agents in malignancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

P53 in cancer: a paradigm for modern management of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

Independent association of angiogenesis index with outcome in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

The p53 tumor suppressor gene: from molecular biology to clinical investigation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

The prognostic significance of angiogenesis in epithelial ovarian carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

Tumor angiogenesis in advanced stage ovarian carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

20 June 2018

The treatment of ties in ranking problems.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

26 November 2018

Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

26 November 2018

Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

26 November 2018

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

26 November 2018

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

26 November 2018

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

26 November 2018

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

26 November 2018

Pretreatment serum hemoglobin level and a preliminary investigation of intratumoral microvessel density in advanced ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

26 November 2018

Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2975758

26 November 2018

The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.016

7 January 2021

Ovarian cancer p53 mutation is associated with tumor microvessel density

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.016

7 January 2021

Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.016

7 January 2021

Potential predictors of chemotherapy response in ovarian cancer--how do we define chemosensitivity?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.016

7 January 2021

Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.016

7 January 2021

Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.016

7 January 2021

Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.016

7 January 2021

Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.08.016

7 January 2021

Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/20870280

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.YGYNO.2010.08.016

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30497303&oldid=2208711945"